Taking the above into consideration, as well as the very low expression levels of WHSC1L1 in normal tissues [19], WHSC1L1 may serve as a promising candidate for drug development for patients with SCCHN as well as other cancer types characterized by WHSC1L1 amplification or overexpression. The gene discussed is NSD3; the disease is cancer.